[Frontiers in Bioscience 14, 3925-3934, January 1, 2009]

Calcium fluxes deregulation in HTLV-I Infected T-cells and malignant transformation

Haidar Akl1, Bassam Badran1, Nabil El Zein2, Gratiela Dobirta1, Arsene Burny1 Philippe Martiat1

1Experimental Hematology, Universite Libre de Bruxelles, Institut Jules Bordet 127 Boulevard de Waterloo, 1000 Bruxelles, Belgium, 2Department of Oncology, Laboratory of Pediatric Oncology, Hôpital des Enfants, Brussels, Belgium

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. The HTLV-I accessory protein p12 (I) and calcium
4. TCR/CD3 signal transduction after HTLV-I infection
5. NFAT and HTLV-I induced CD4+ cell transformation
6. HTLV-I silencing and Calcium
7. HTLV-I infected cells: CD7, Calcium pathways and Apoptosis
7.1. CD7 and ATLL
7.2. CD7 and calcium influx
7.3. Ca2 , apoptosis and cancer
7.4. The PI3K/Akt/Bad pathway alteration following HTLV-I infection and Calcium fluxes modifications
7.5. Galectins, CD7 and apoptosis
8. Conclusions and perspectives
9. Acknowledgements
10. References

1. ABSTRACT

The CD4+ T-cell malignancy induced by human T-cell leukemia virus type 1 (HTLV-I) infection and termed; Adult T-cell Leukemia lymphoma (ATLL), is caused by defects in the mechanisms underlying cell proliferation and cell death. In the CD4+ T-cells, calcium ions are central for both phenomena. ATLL is associated with a marked hypercalcemia in many patients. The consequence of a defect in the Ca2+ signaling pathway for lymphocyte activation is characterized by an impaired NFAT activation and transcription of cytokines, chemokines and many other NFAT target genes whose transcription is essential for productive immune defense. Fresh ATLL cells lack the TCR/CD3 and CD7 molecules on their surface. Whereas CD7 is a calcium transporter, reduction in calcium influx in response to T-cell activation was reported as a functional consequence of TCR/CD3 expression deficiency. Understanding these changes and identifying the molecular players involved might provide further insights on how to improve ATLL treatment.